Table 3

Characteristics of studies that examined MDM2 SNP rs2279744

ReferenceOR (95% CI)P valuesEAFAncestryCases (n)Controls (n)EC typeDataset(s)
Terry 200848 1.32 (1.11 to 1.56)0.002N/AEuropean5911543N/ANHS (Nurses’ Health Study), WHS (Women’s Health Study)
Ashton 200949 1.37 (1.06 to 1.79)N/A0.56Caucasian191291AllHospital based
Nunobiki 200950 2.28 (2.02 to 2.54)0.0300.49Japanese10295AllHospital based
Ueda 200951 1.91 (1.5 to 3.47)0.0350.51Japanese119108AllHospital based
Wan 201143 1.54 (1.21 to 1.94)0.000N/AN/AN/AN/AN/AWalsh 2007,36 Terry 2008, Ashton 2009, Nunobiki 2009, Ueda 2009
Li 201144 1.75 (1.16 to 2.63)0.007N/AEuropean, Asian10011889N/AWalsh 2007, Terry 2008, Ashton 2009, Nunobiki 2009, Ueda 2009
Knappskog 201240 1.22 (1.03 to 1.44)N/A0.36European392956N/AHospital based
Zajac 201227 1.33 (1.12 to 1.58)0.001N/AEuropean152100N/AHospital based
Yoneda 201352 1.64 (0.81 to 3.28)0.4500.45Asian125200AllPopulation based
Peng 201341 1.6 (1.21 to 2.13)0.001N/AEuropean, Asian20694546N/AWalsh 2007, Terry 2008, Ashton 2009, Nunobiki 2009, Knappskog 2012, Yoneda 2013
1.87 (1.29 to 2.73)0.010N/AEuropean18424251N/A
Zhao 201453 1.41 (1.04 to 1.92)0.030N/AEuropean, Asian12782189N/AWalsh 2007, Terry 2008, Ashton 2009, Ueda 2009, Zajac 2012, Yoneda 2013
1.34 (1.07 to 1.69)N/AN/AEuropean8591707N/A
Wang 201438 1.32 (1.06 to 1.64)0.010N/AEuropean, Asian19674460N/AWalsh 2007, Terry 2008, Ashton 2009, Nunobiki 2009, Ueda 2009, Zajac 2012, Knappskog 2012, Yoneda 2013
1.14 (0.79 to 1.65)0.490N/AEuropean17694172N/A
Xue 201642 1.46 (1.25 to 1.72)N/AN/AEuropean16904151N/AWalsh 2007, Terry 2008, Ashton 2009, Nunobiki 2009, Ueda 2009, Zajac 2012, Knappskog 2012, Yoneda 2013
Zhang 201854 1.91 (1.5 to 3.47)0.035N/AEuropean, Asian7621041N/AWalsh 2007, Terry 2008, Ashton 2009, Nunobiki 2009, Ueda 2009, Zajac 2012
Zou 201855 1.23 (1.06 to 1.41)0.005N/AEuropean, Asian, mixed35356476AllWalsh 2007, Terry 2008, Ashton 2009, Ueda 2009, Knappskog 2012, Zajac 2012, Yoneda 2013, Okamoto 2015, Gansmo 201737
  • *Walsh et al 2007 and Gansmo et al 2017 did not meet eligibility criteria for us to include in our evaluation.

  • EAF, effect allele frequency; EC, endometrial cancer; SNP, single nucleotide polymorphism.